Received Aug 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y000205 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Y014059 | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | R017134 | — |
No side effects reported. No additional information on AE/No PQC; did not receive her second and third doses until November 2024 and January 2025; did not receive her second and third doses until November 2024 and January 2025; This spontaneous report was received from a consumer and refers to her 16-year-old daughter. The patient's medical history, concurrent conditions, and cncomitant therapies were not reported. In 2019 (when 11 years old), the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Suspension for injection (lot #R017134, expiration date: 29-Apr-2021). The second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Suspension for injection (lot #Y000205, expiration date: 23-Sep-2026) was administered in November 2024; the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) Suspension for injection (lot #Y014059, expiration date: 01-Nov-2026) was administered in January 2025 (inappropriate schedule of vaccine administration). No adverse event was reported.